Nichiban Co., Ltd.

Nichiban Co., Ltd. manufactures and sells medical products and tapes in Asia and Europe. It offers medical products, including surgical tapes, dressing tapes, first-aid bandages, hemostatic bandages, and others. The company also provides OTC products, such as anti-inflammatory patches, foot care products, waterproof films, and bandages. In addition, it offers taping tapes comprising cotton, elastic, kinesiology, strapping tapes, and others; and stationery products consisting of cellulose adhesive tapes, double sided tapes, adhesive transfer tapes, book binding tapes, and others. Further, the company provides industrial tapes for non-heavy duty packaging, carton boxes, agricultural use, vehicles, and machinery, as well as specialized tapes; and cellulose, OPP packing, kraft paper, lithographic, and crepe tapes. Nichiban Co., Ltd. was founded in 1918 and is headquartered in Tokyo, Japan.

Nichiban Co., Ltd. trades as NHBAF on OTC. The company is classified in Industrials / Business Equipment & Supplies and reports in USD.

The current profile places the business in Business Equipment & Supplies. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $49.46B of revenue and $1.96B of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Nichiban Co., Ltd. can be compared against peers such as Alfen N.V., DMCI Holdings, Inc., Mo-BRUK S.A., Novonix Limited, PowerCell Sweden AB (publ), Qingling Motors Co., Ltd..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $258.54M, beta of 0.20, and return on equity of +4.5%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

NHBAF currently shows total debt of $2.13B and beta of 0.20. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.nichiban.co.jp

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.